Showing : 19–27 of 93
WEDNESDAY, Feb. 22, 2017 (HealthDay News) — For patients with type 2 diabetes and acute coronary syndrome (ACS), adiponectin concentration is associated with increased risk of certain cardiovascular (CV) outcomes, according to a study published online Feb. 14 in Diabetes, Obesity and Metabolism.
Attending ACC in March? Want to see and hear about what's going at Baim Institute for Clinical Research? Stop by our booth to connect/reconnect! Our booth will be set up during all of the exhibit hours; stop by and say "hi"! Friday, March 17, 9:30 a.m. – 4:45 p.m. Saturday, March 18, 9:30 a.m. – 4:45 p.m. Sunday, March 19, 9:30 a.m. – 2:00 p.m.
Students, Faculty, Researchers, and Patients to Benefit from New Collaboration
•Over 2,700 atrial fibrillation (AF) patients undergoing a percutaneous coronary intervention (PCI) with stenting randomized in Boehringer Ingelheim sponsored RE-DUAL PCI™ trial 1,2 •First PCI study to evaluate the safety of a dual versus triple antithrombotic regimen using non-vitamin K antagonist oral anticoagulant (NOAC) dosages already approved for AF-stroke prevention •The results will support physicians in choosing an optimal antithrombotic regimen for AF patients who require a PCI
Stop by Baim Institute for Clinical Research's booth at TCT! Booth #2050 Sunday, October 30th - Tuesday, November 1st.
Baim Institute's Chief Scientific Advisor, Dr. Laura Mauri will be engaged in several presentations and discussions at TCT.
Baim Institute for Clinical Research faculty member, Dr. Robert Yeh will be moderating and lecturing at TCT.
Academic Research Organization HCRI Changes Name to Baim Institute for Clinical Research